Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Recognition of specific antigen through the B-cell receptor (BCR) stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of ...

No evidence for alteration in B cell cytokine profiles is available Evidence that rituximab affects T-cell activation by B cells includes reduced T-cell expression of HLA-DR, CD154 and CD69 ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...